Journal article icon

Journal article

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

Abstract:

CONTEXT: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial. OBJECTIVE: To determine the efficacy, safety, and tolerability of tarenflurbil. DESIGN, SETTING, AND PATIENTS: A multicenter, randomized, double-blind, placebo-controlled trial enrolling patients with mild ...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1001/jama.2009.1866

Authors


Expand authors...
Journal:
JAMA
Volume:
302
Issue:
23
Pages:
2557-2564
Publication date:
2009-12-05
DOI:
EISSN:
1538-3598
ISSN:
0098-7484
URN:
uuid:e0405ec3-3420-4d6f-b742-8b4b0969bf7e
Source identifiers:
60834
Local pid:
pubs:60834

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP